Who
Steve Pakola
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, Regenxbio; Chief Medical Officer, Whitehawk Therapeutics.
In numbers
- Trades disclosed
- 54
- Buys
- 0
- Sells
- 9
- Bought
- $0
- Sold
- $2.7M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 23 Apr 2018
- Last trade
- 1 Aug 2026
- Last filed
- 4 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 1 Aug 2026filed 4 Aug 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $72K7,468 at $9.69 | filing |
| 1 Aug 2026filed 4 Aug 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code F | $72K7,468 at $9.69 | filing |
| 2 Jul 2026filed 6 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code M | $17K2,161 at $7.86 | filing |
| 2 Jul 2026filed 6 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $29K2,161 at $13.64 | filing |
| 2 Jul 2026filed 6 Jul 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code M | —2,161 at $0.00 | filing |
| 2 Jul 2026filed 6 Jul 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code M | —2,161 at $0.00 | filing |
| 2 Jul 2026filed 6 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code M | $17K2,161 at $7.86 | filing |
| 2 Jul 2026filed 6 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $29K2,161 at $13.64 | filing |
| 1 Jul 2026filed 1 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code M | $289K36,725 at $7.86 | filing |
| 1 Jul 2026filed 1 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $472K36,725 at $12.86 | filing |
| 1 Jul 2026filed 1 Jul 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code M | —36,725 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | RGNX Regenxbiooption or derivative · Biotechnology | SEC FORM 4 Code M | —36,725 at $0.00 | filing |
| 1 Jul 2026filed 1 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Code M | $289K36,725 at $7.86 | filing |
| 1 Jul 2026filed 1 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $472K36,725 at $12.86 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $216K19,608 at $11.04 | filing |
| 29 Jun 2026filed 1 Jul 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $216K19,608 at $11.04 | filing |
| 11 May 2026filed 13 May 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $169K15,309 at $11.02 | filing |
| 11 May 2026filed 13 May 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $169K15,309 at $11.02 | filing |
| 10 Mar 2026filed 12 Mar 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $53K5,124 at $10.35 | filing |
| 10 Mar 2026filed 12 Mar 2026 | RGNX RegenxbioBiotechnology | SEC FORM 4 Sold | $53K5,124 at $10.35 | filing |
News
No headline names them, or the companies they trade most, lately.